Yang Limin, Xiao Aibo, Wang Hu, Zhang Xiaojuan, Zhang Yuan, Li Yunlong, Wei Yanqiu, Liu Wenjun, Chen Chuangfu
College of Animal Science and Technology, Shihezi University, Shihezi 832003, China.
CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China.
Vaccines (Basel). 2022 Jan 26;10(2):197. doi: 10.3390/vaccines10020197.
Japanese encephalitis virus (JEV) is the leading cause of epidemic encephalitis in Asia, and vaccination is the most effective way to prevent JE. Although several licensed vaccines were widely used, there is still a demand for developing safer, cheaper, and more effective JE vaccines. In the current study, a virus-like particle (VLP) vaccine candidate containing the envelope structural protein of JEV expressed by the was assembled in vitro. It elicited a robust humoral and cellular immune response in mice model, conferring immunodeficient mice complete protection against lethal doses of JEV challenge. Furthermore, pigs immunized with VLP alone without adjuvant via intramuscular produced high neutralizing antibodies against JEV. Consequently, this study showed a new design of JEV subunit vaccine based on VLP strategy and demonstrated the potential for clinical application.
日本脑炎病毒（JEV）是亚洲流行性脑炎的主要病因，接种疫苗是预防日本脑炎最有效的方法。尽管几种已获许可的疫苗被广泛使用，但仍有开发更安全、更便宜且更有效的日本脑炎疫苗的需求。在当前研究中，一种包含由[具体表达系统]表达的JEV包膜结构蛋白的病毒样颗粒（VLP）候选疫苗在体外组装。它在小鼠模型中引发了强烈的体液和细胞免疫反应，使免疫缺陷小鼠对致死剂量的JEV攻击具有完全保护作用。此外，通过肌肉内途径单独用VLP免疫且无佐剂的猪产生了针对JEV的高中和抗体。因此，本研究展示了基于VLP策略的日本脑炎亚单位疫苗的新设计，并证明了其临床应用潜力。
